摘要
目的:探讨切除修复交叉互补基因(ERCC1)mRNA表达及118C/T基因多态性与胃癌对奥沙利铂辅助化疗预后的关系。方法:根治术后胃癌患者62例,采用奥沙利铂为主的方案进行辅助化疗。采用半定量RT-PCR方法检测胃癌组织中ERCC1 mRNA水平。采用PCR-LDR(连接酶检测反应)检测ERCC1118C/T基因多态。结果:62例胃癌组织ERCC1 mRNA表达水平的中位值为0.672;ERCC1118C/C、C/T和T/T基因型分别占51.6%(32/66)、43.5%(27/62)和4.8%(3/62)。ERCC1 mRNA高表达组(>0.672)无复发生存率和总生存率均显著低于低表达组(P<0.05);携带C/T和T/T基因型患者与C/C基因型患者的无复发生存率和总生存率差异无显著性(P>0.05)。多因素分析结果显示ERCC1 mRNA水平是影响患者预后的独立危险因素(P<0.05),而ERCC1118C/T多态与预后无关(P>0.05)。结论:ERCC1 mRNA表达水平与接受奥沙利铂为主辅助化疗胃癌患者的预后有关,可用于其预后预测。
Objective：To investigate the association of ERCC1 mRNA levels and ERCC1 118 C/T polymorphism with the clinical outcome of gastric cancer patients treated with oxalipatinum-based adjuvant chemotherapy. Methods：Sixty-two gastric cancer patients received oxalipatinum-based adjuvant chemotherapy. The intratumoral ERCC1 mRNA expression was tested by semi-quantitative RT- PCR, and ERCCI ll8 C/T polymorphism was tested by PCR-LDR（ligation detection reaction） method. Results：The median ERCC1 RNA level in 62 gastric cancer tissues was 0.672. The frequencies of ERCC1 118 C/C,C/T and T/T genotype were 51.6%（32/66）, 43.5%（27/62） and 4.8%（3/62）,respectively. The recurrence-free and overall survival rate in patients with low level of ERCC1 mRNA （〉0.672）were significantly higher than those in patients with high level（P 〈 0.05）,while there was no significant difference found between patients with ERCC1 118 C/C and variant genotypes（T/T or C/T）. Multivariate analysis showed that ERCC1 mRNA level was a potential predictor for relapse and survival in gastric cancer patients treated with platinum-based adjuvant chemotherapy （P 〈 0.05）. ERCC 1 118 C/T polymorphism was not associated with the disease prognosis. Conclusion：The ERCC 1 mRNA level might be a useful predictive parameter for the relapse and survival of gastric cancer patients received with oxalipatinum-based adjuvant chemotherapy
出处
《南京医科大学学报（自然科学版）》
CAS
CSCD
北大核心
2008年第4期453-456,共4页
Journal of Nanjing Medical University(Natural Sciences)
基金
无锡市科技局社会发展计划(CS055012
CLZ00612)
